2022 ASCO Annual Meeting

Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA3505